Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 4/20 | 0.37 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.33 |
| ▸ | RXRB | P28702 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7602939 | 0.89 | LMNA (0.43) | LMNASMN1; SMN2HPGDTSHRPKM | |
| SCHEMBL5503597 | 0.73 | LMNA (0.45) | LMNASMN1; SMN2HPGDTSHRPKM | |
| SCHEMBL29482311 | 0.72 | LMNA (0.67) | LMNASMN1; SMN2PTK2BHPGDTSHR | |
| SCHEMBL30657703 | 0.72 | LMNA (0.67) | LMNASMN1; SMN2PTK2BHPGDTSHR | |
| SCHEMBL7600529 | 0.72 | LMNA (0.41) | LMNASMN1; SMN2PTK2BHPGDTSHR | |
| SCHEMBL1070126 | 0.72 | LMNA (0.67) | LMNASMN1; SMN2PTK2BHPGDTSHR | |
| SCHEMBL1377760 | 0.72 | LMNA (0.67) | LMNASMN1; SMN2PTK2BHPGDTSHR | |
| SCHEMBL11553081 | 0.72 | LMNA (0.43) | LMNASMN1; SMN2HPGDTSHRPKM | |
| SCHEMBL11677163 | 0.72 | LMNA (0.43) | LMNASMN1; SMN2HPGDTSHRPKM | |
| SCHEMBL2035293 | 0.70 | LMNA (0.69) | LMNASMN1; SMN2PTK2BHPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS, INC. | 2017-07-27 | — | — | US | disclosed |
| US-9637515-B2 | Guggulphospholipid methods and compositions | JINA PHARMACEUTICALS, INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2088865-B1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | JINA PHARMACEUTICALS, INC. (US) | 2010-06-17 | — | — | US | disclosed |
| EP-2088865-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | Jina Pharmaceuticals Inc. (US) | 2009-08-19 | — | — | EP | disclosed |
| WO-2008058156-A9 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC (US) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008058156-A2 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | JINA PHARMACEUTICALS INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100151002-A1 | Guggulphospholipid Methods and Compositions | SGMS2, SGMS1, PLA2G5 | LMNA 1323/4885SMN1; SMN2 3094/4885PTK2B 4549/4885 |
| US-20170210775-A1 | GUGGULPHOSPHOLIPID METHODS AND COMPOSITIONS | SGMS1, SGMS2, GGPS1 | LMNA 1667/4885SMN1; SMN2 3304/4885PTK2B 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.